Holen Sie sich die Stockscreener-App
27.69
2.94%
0.79
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Trend Recap: Is Oculis Holding AG Equity Warrant a top pick in the sector2025 Pullback Review & Long-Term Growth Stock Strategies - baoquankhu1.vn
Jobs Data: Can Oculis Holding AG beat the S P 500Gold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Aug Highlights: Will Oculis Holding AG benefit from rate cutsMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Market Review: Is Oculis Holding AG Equity Warrant benefiting from innovation trendsJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy - MSN
Oculis Holding AG (OCS) Stock Analysis: Unveiling A 68% Upside Potential For Investors - DirectorsTalk Interviews
Oculis (NASDAQ:OCS) Hits New 12-Month HighShould You Buy? - MarketBeat
Oculis Holding AG's (NASDAQ:OCS) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$130m Last Week - 富途牛牛
Market Fear: Is Oculis Holding AG Equity Warrant forming higher highs and higher lows2025 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Portfolio Update: Will IPGP outperform tech stocksTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Update Report: Can Oculis Holding AG continue delivering strong returnsDay Trade & Safe Capital Allocation Plans - baoquankhu1.vn
Is Oculis Holding AG Equity Warrant stock positioned for digital transformation2025 Earnings Impact & Free High Return Stock Watch Alerts - bollywoodhelpline.com
Oculis (NASDAQ:OCS) Reaches New 1-Year HighHere's Why - MarketBeat
Trading Systems Reacting to (OCS) Volatility - Stock Traders Daily
Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation - Sahm
OCS: Late-stage pipeline targets DME, dry eye, and neuroprotection, with major milestones in 2024–2027 - TradingView
US Market Wrap: How does Oculis Holding AG compare to its peersJuly 2025 News Drivers & Community Consensus Stock Picks - baoquankhu1.vn
Forecast Cut: How does Hubbell Incorporated correlate with NasdaqInflation Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50 - Defense World
Oculis Holding AG (NASDAQ:OCS) Sees Significant Growth in Short Interest - MarketBeat
Market Outlook: Is Oculis Holding AG Equity Warrant a top pick in the sectorWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis - Yahoo Finance
Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis - simplywall.st
Why Oculis Holding AG stock could benefit from AI revolutionWeekly Trade Recap & Technical Pattern Based Signals - Улправда
Is Oculis Holding AG stock recession proofEarnings Growth Report & Smart Money Movement Alerts - Улправда
Oculis (NASDAQ:OCS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis - Indian Pharma Post
Why Oculis Holding AG Equity Warrant stock could rally in 2025 - Улправда
Can Oculis Holding AG Equity Warrant stock beat analyst upgradesJuly 2025 Spike Watch & Reliable Breakout Forecasts - Улправда
Will Oculis Holding AG stock maintain momentum in 2025Trade Exit Report & Expert Curated Trade Ideas - Улправда
IPO Launch: Why Oculis Holding AG stock is recommended by analystsWeekly Profit Report & Free Reliable Trade Execution Plans - Улправда
Can Oculis Holding AG (CR5) stock surprise with quarterly resultsMarket Movement Recap & Long-Term Capital Growth Ideas - ulpravda.ru
Why Oculis Holding AG Equity Warrant stock attracts global investorsCandlestick Trading Patterns & Low Risk Trading Plans - bollywoodhelpline.com
Weekly Earnings: Can Oculis Holding AG Equity Warrant stock beat analyst upgradesQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Will Oculis Holding AG Equity Warrant stock deliver consistent dividendsJuly 2025 Update & Long-Term Safe Investment Ideas - Улправда
Why Oculis Holding AG stock is recommended by analysts2025 Price Momentum & Low Risk High Reward Ideas - Улправда
OCSOculis Holding Latest Stock News & Market Updates - Stock Titan
Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline - marketscreener.com
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyFibonacci Retracement Levels & Unlock Smart Investment Tactics That Work - Улправда
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference - The Manila Times
Oculis Holding AG Advances PIONEER Program with Breakthrough Therapy Designation for Privosegtor and Prepares for Upcoming J.P. Morgan Healthcare Conference Presentation - Quiver Quantitative
Oculis to Showcase Transformative Late-stage Pipeline in - GlobeNewswire
FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis - Eyes On Eyecare
Should I hold or sell Oculis Holding AG Equity Warrant stock in 20252026 world cup usa national team qualification goalkeepers transition play odds analysis insights - ulpravda.ru
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2026 world cup usa national team qualification star players transition play knockout prediction guide - Улправда
What drives Oculis Holding AG stock priceDouble Top/Bottom Patterns & Free Stay Ahead With Picks - earlytimes.in
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis - Ophthalmology Times
Oculis gains on FDA breakthrough therapy status (OCS:NASDAQ) - Seeking Alpha
Oculis stock surges after FDA grants breakthrough therapy designation By Investing.com - Investing.com Nigeria
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):